S-921-119
Held at the desk.
Sponsored by Jim Banks (R-IN)
What it does
Tyler's Law would require the Secretary of Health and Human Services (HHS) to complete a study within 3 years examining how frequently hospital emergency departments test overdose patients for fentanyl, the costs and benefits of such testing, privacy implications, staff training needs, and barriers to implementation. Within 9 months after the study is complete, HHS would be required to issue non-binding guidance on whether fentanyl testing should become a routine procedure for overdose patients, and how hospitals can best implement it.
Who benefits
Overdose patients who may receive more accurate diagnoses and targeted treatment if fentanyl testing becomes more routine. Emergency department physicians and nurses who would gain clearer federal guidance on testing protocols. Hospitals seeking standardized best practices to reduce liability and improve outcomes. Public health researchers who would gain new federal data on fentanyl testing rates. Families of overdose victims who may benefit from improved survival rates if testing leads to better treatment decisions. Fentanyl test strip and drug screening manufacturers who may see increased demand.
Who is hurt
Hospitals and health systems that may face administrative burden or cost pressure if the guidance leads to broader adoption of routine testing. Overdose patients with privacy concerns, as more detailed toxicology data in medical records could affect insurance, employment, or legal proceedings — though the bill explicitly requires the study to examine HIPAA protections. Taxpayers who fund the HHS study and guidance process. State and local health agencies that may face pressure to align their own protocols with federal guidance.
Supporters argue
Supporters argue that fentanyl is now involved in the majority of U.S. overdose deaths — over 73,000 in 2022 according to CDC data — yet emergency departments lack consistent protocols for detecting it, since standard drug panels often do not screen for fentanyl or its analogs. They contend that without reliable federal data on current testing practices, hospitals cannot make evidence-based decisions, and that this bill takes a measured first step by gathering facts before mandating any change in clinical practice.
Opponents argue
Opponents argue that the bill produces only non-binding guidance after a multi-year study, meaning it may have little practical effect on emergency department behavior or overdose outcomes. They contend that the 3-year study timeline plus 9-month guidance period means no actionable federal direction for nearly four years, during which tens of thousands of additional overdose deaths may occur — and that Congress could instead directly fund fentanyl testing equipment or mandate reporting requirements to achieve faster, measurable results.
Constitutional context
Congress has broad authority to direct HHS studies and issue guidance under the Spending Clause (Art. I, §8, cl. 1) and the Necessary and Proper Clause (Art. I, §8, cl. 18). Because this bill does not mandate clinical practices, impose conditions on federal funding, or compel state action, it does not raise the spending clause coercion concerns identified in NFIB v. Sebelius (2012), nor does it present a significant Commerce Clause question.
Checks and balances
The executive branch (HHS/SAMHSA) gains a directed research and guidance-issuing role, but the guidance is non-binding; Congress retains oversight authority and could legislate further based on study findings.
Historical precedent
Congress has previously directed HHS to conduct studies and issue guidance on specific clinical practices, such as the opioid prescribing guidelines process that led to the CDC's 2016 and 2022 Opioid Prescribing Guidelines, which followed a similar study-then-guidance structure.